Newsfile Corp
14 Jun 2026, 11:20 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is accused of using channel stuffing to report 20% revenue growth in 2025 when real growth was allegedly -3%. — Allegations of systemic revenue inflation and financial fraud typically lead to massive valuation write-downs and loss of investor trust.
-0.90A federal securities class action lawsuit has been filed against ADMA Biologics alleging violations of federal securities laws. — Class action lawsuits create significant legal liabilities and potential cash outflows for the company.
-0.60The company is alleged to have engaged in an undisclosed related party transaction and lacked adequate internal controls. — Poor internal controls and undisclosed related-party deals suggest governance failures and increase the risk of further accounting surprises.
-0.50Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a federal securities class action lawsuit alleging fraud, channel stuffing, and misleading financial statements.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Newsfile Corp
3h ago
